RVMD

Revolution Medicines

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 1

consensus rating "Strong Buy"

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About RVMD

Revolution Medicines, Inc.

A clinical-stage oncology company that developing novel targeted therapies for RAS-addicted cancers

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

02/13/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

534

Fiscal Year Ends

12-31

Website

www.revmed.com

Security Type

Common stock

Office address

700 Saginaw Drive, Redwood City, California 94063

Business

Introduction

Revolution Medicines, Inc., founded in October 2014, is a Delaware corporation. The company is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit cutting-edge targets in RAS addictive cancer. The company has advanced structure-based drug discovery capabilities based on deep knowledge of chemical biology and cancer pharmacology and innovative proprietary technologies to create small molecules suitable for unconventional binding sites. The company's understanding of cancer's genetic drivers and adaptive resistance mechanisms, coupled with strong drug discovery and pharmacochemistry capabilities, has guided the establishment of a deep pipeline for key signaling nodes in the RAS pathway and related pathways.

Company Financials

EPS

RVMD has released its 2024 Q4 earnings. EPS was reported at -1.12, versus the expected -0.96, missing expectations. The chart below visualizes how RVMD has performed over recent quarters, highlighting trends in earnings surprises.